Aqtual Strengthens Executive Leadership to Advance Active Chromatin cfDNA Diagnostics and Precision Medicine Platform
Aqtual, Inc., a precision medicine company focused on developing next-generation diagnostics based on active chromatin cell-free DNA (cfDNA), has announced the appointment of Ferhan Qureshi as Chief Technology Officer (CTO) and Bill Arteca as Head of Biospecimen Strategy. The two executive hires represent an important step in the company’s growth as it prepares to advance its lead therapy-selection diagnostic through clinical validation and commercialization while expanding collaborations with pharmaceutical and biotechnology partners.
The appointments come at a pivotal stage for Aqtual as it continues to develop its proprietary functional liquid biopsy platform, which is designed to provide physicians and researchers with deeper biological insights by analyzing active chromatin fragments circulating in the bloodstream. The company believes this technology has the potential to improve treatment selection, accelerate biomarker discovery, and support precision medicine across autoimmune diseases, oncology, and drug development.
By bringing together experienced leaders with backgrounds spanning molecular diagnostics, laboratory operations, commercialization, and biospecimen strategy, Aqtual aims to strengthen the infrastructure needed to transition its scientific innovations into clinically deployable products.
Expanding Leadership to Support Growth
As precision medicine continues to evolve, biotechnology companies face increasing demands to transform promising research into products that can be reliably used in clinical practice. Successfully making that transition requires expertise across multiple disciplines, including technology development, regulatory compliance, laboratory operations, manufacturing, commercialization, and clinical validation.
Aqtual’s latest leadership appointments are intended to support this next phase of development.
The company has already demonstrated the scientific foundation of its active chromatin cfDNA platform and is now focusing on scaling its technology for broader clinical and commercial applications.
The addition of experienced executives reflects Aqtual’s strategy of strengthening operational capabilities while expanding relationships with healthcare providers, pharmaceutical companies, and research organizations.
Ferhan Qureshi Appointed Chief Technology Officer
Ferhan Qureshi joins Aqtual with more than 25 years of experience in molecular diagnostics and biotechnology.
Throughout his career, he has helped guide complex molecular technologies from early research through product development and clinical implementation.
His professional background includes leadership roles at several prominent life science organizations, including:
- Genentech
- Crescendo Bioscience
- Octave Bioscience
Across these organizations, Mr. Qureshi has contributed to multiple areas essential for successful diagnostic product development.
His experience includes:
- Molecular assay development
- Clinical laboratory operations
- Regulatory strategy and execution
- Product commercialization
- Technology deployment
At Aqtual, he will oversee the continued development of the company’s active chromatin cfDNA platform while helping transition the technology into scalable products suitable for both clinical diagnostics and pharmaceutical research applications.
Focus on Clinical Translation
One of Mr. Qureshi’s primary responsibilities will involve ensuring that Aqtual’s scientific discoveries maintain their analytical rigor throughout the development process.
Moving innovative diagnostic technologies from laboratory research into clinical practice often presents significant challenges.
Diagnostic assays must demonstrate:
- Analytical accuracy
- Clinical validity
- Reproducibility
- Regulatory compliance
- Operational scalability
Maintaining scientific integrity throughout these stages is critical to ensuring physicians can rely on diagnostic results when making treatment decisions.
Aqtual believes Mr. Qureshi’s experience will help guide this process as the company advances its first commercial products.
Bill Arteca Named Head of Biospecimen Strategy
Aqtual has also appointed Bill Arteca as Head of Biospecimen Strategy.
Mr. Arteca brings extensive expertise in biospecimen acquisition, management, and strategic program development.
Prior to joining Aqtual, he founded BioSample Connect, a biospecimen platform that was later acquired by Joined Bio.
Following the acquisition, he continued to lead growth and operational activities supporting biospecimen services.
Throughout his career, Mr. Arteca has worked with healthcare organizations, research institutions, and industry partners to establish biospecimen programs supporting biomarker research and therapeutic development.
His experience spans:
- Biospecimen sourcing
- Clinical sample management
- Biomarker discovery
- Clinical validation studies
- Strategic research partnerships
Importance of Biospecimens in Precision Medicine
High-quality biospecimens play an essential role in modern precision medicine.
Reliable biological samples are necessary for:
- Biomarker identification
- Diagnostic development
- Clinical trial support
- Drug discovery
- Validation studies
As Aqtual expands its liquid biopsy platform into multiple disease areas, establishing robust biospecimen infrastructure becomes increasingly important.
Mr. Arteca will lead efforts to strengthen the company’s biospecimen strategy while supporting collaborations with pharmaceutical companies pursuing biomarker-driven drug development.
These initiatives are expected to help accelerate both internal diagnostic programs and external research partnerships.
CEO Highlights Company’s Next Phase
Diana Abdueva, Ph.D., Founder and Chief Executive Officer of Aqtual, described the appointments as an important milestone in the company’s evolution.
According to Dr. Abdueva, Aqtual has already demonstrated the scientific feasibility of its platform.
The company’s next objective is focused on disciplined execution—transforming innovative science into diagnostic products that physicians can confidently incorporate into patient care.
She emphasized that this transition requires building both reliable products and the organizational infrastructure necessary to support future growth.
Dr. Abdueva noted that both Mr. Qureshi and Mr. Arteca have extensive experience guiding similar transitions throughout their careers and expressed confidence that their leadership will help shape Aqtual’s future.
Advancing Rheumatoid Arthritis Therapy Selection
Aqtual’s lead clinical program is a therapy-selection diagnostic for rheumatoid arthritis (RA).
The test is designed to help predict which advanced therapy is most likely to benefit an individual patient before treatment begins.
Selecting the optimal therapy remains one of the major challenges in rheumatoid arthritis management.
Although numerous biologic and targeted therapies are available, patients often respond differently to individual medications.
Current treatment strategies frequently involve trial-and-error approaches that may require months before determining whether a therapy is effective.
A predictive diagnostic capable of identifying likely responders before treatment could potentially reduce delays, minimize unnecessary medication exposure, and improve patient outcomes.
Expanding Beyond Rheumatoid Arthritis
While rheumatoid arthritis represents the company’s first clinical diagnostic application, Aqtual intends to extend its technology across additional disease areas.
The active chromatin cfDNA platform is being evaluated for use in:
- Autoimmune diseases
- Oncology
- Biopharmaceutical research
- Drug development
- Biomarker discovery
Because the technology measures functional biological activity rather than simply detecting genetic mutations, the company believes it may provide unique insights into disease mechanisms and therapeutic response.
This broader applicability positions the platform for potential expansion across multiple areas of precision medicine.
Understanding Active Chromatin Cell-Free DNA
Traditional liquid biopsy technologies often focus on detecting genetic mutations or fragmented DNA circulating in the bloodstream.
Aqtual’s platform takes a different approach by analyzing active chromatin cell-free DNA.
Chromatin refers to the complex of DNA and associated proteins that regulate gene activity inside cells.
When cells release fragments of active chromatin into circulation, these fragments may contain information reflecting ongoing biological processes rather than only static genetic information.
According to the company, measuring active chromatin cfDNA enables a functional liquid biopsy, providing insight into which genes are actively involved in disease at a given point in time.
This information may help physicians better understand disease activity and predict therapeutic response.
Potential Applications in Drug Development
Beyond clinical diagnostics, Aqtual sees significant opportunities for its platform within pharmaceutical research.
Drug developers increasingly rely on biomarkers to:
- Identify appropriate patients
- Monitor treatment response
- Evaluate therapeutic mechanisms
- Improve clinical trial efficiency
Functional liquid biopsy technologies capable of providing dynamic biological information may complement traditional genomic testing during drug development.
The company is actively expanding strategic partnerships with biopharmaceutical organizations interested in applying the platform to therapeutic research.
CTO Shares Vision
Commenting on his appointment, Mr. Qureshi described Aqtual’s demonstration of functional liquid biopsy technology through active chromatin cell-free DNA analysis as an important advancement for precision medicine.
He noted that much of his career has focused on ensuring innovative molecular technologies maintain their scientific quality as they move from research into clinical implementation.
According to Mr. Qureshi, he is excited to work alongside Aqtual’s scientific team to unlock the platform’s full potential for both pharmaceutical partners and healthcare providers.
He emphasized that successful translation of complex molecular technologies into clinical products has the potential to improve patient care while supporting more effective drug development.
Preparing for Commercialization
As Aqtual advances toward the next stages of clinical validation, the company is simultaneously building the operational infrastructure required for commercialization.
Key priorities include:
- Product validation
- Clinical evidence generation
- Laboratory scalability
- Regulatory preparation
- Commercial deployment
- Strategic partnerships
Strengthening executive leadership across both technology development and biospecimen strategy supports these objectives while positioning the company for future growth.
The appointments of Ferhan Qureshi as Chief Technology Officer and Bill Arteca as Head of Biospecimen Strategy mark an important step in Aqtual’s evolution from a research-focused biotechnology company toward a commercial precision medicine organization. Their combined expertise in molecular diagnostics, clinical laboratory operations, biospecimen management, and product commercialization strengthens the company’s leadership as it advances its active chromatin cfDNA platform toward clinical application.
With its lead rheumatoid arthritis therapy-selection diagnostic progressing through late-stage development and broader expansion planned across autoimmune diseases, oncology, and pharmaceutical research, Aqtual continues to position its functional liquid biopsy technology as a platform capable of supporting more personalized treatment decisions and accelerating the future of precision medicine.
About Aqtual, Inc.
Aqtual, Inc. is a precision medicine company developing products for chronic disease management and oncology utilizing a novel cell-free DNA-based platform. Aqtual’s proprietary platform evaluates protein regulation, epigenetics, and transcriptomics solely using cell-free DNA fragments found in the blood. The platform yields efficient and robust real-time analysis of disease and treatment while overcoming the limitations of previous cell-free DNA methodologies.